HCPCS Q2054
Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
HCPCS Information
- HCPCS Code: Q2054
- The Healthcare Common Procedure Coding System (HCPCS) is a set of unique alphanumeric codes used to report medical procedures and services to healthcare programs like Medicare and Medicaid. HCPCS codes are used in conjunction with NDC codes for billing and medical documentation puporses. For instance, HCPCS Q2054 identifies the type of service or supply used while any of the 1 NDC codes below could be used to specify the exact drug used.
- Short Description
- Lisocabtagene mara car pos t
- Long Description
- Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Pricing Indicator
- Drugs
- Multiple Pricing Indicator
- Not applicable as HCPCS priced under one methodology
- Coverage Description
- Carrier judgment
- BETOS Type of Service
- Other drugs
- Medicare Payment Limit
- $541,635.66
- Medicare Co-Insurance Percentage
- 18.687%
- Medicare Pricing Notes
- Inflation-adjusted coinsurance
- HCPCS Classification
- List of HCPCS codes for: Temporary Codes (Q-codes)
HCPCS Crossover to NDC Codes
The NDC codes below allow precise billing based on the specific manufacturer and medication used:
| NDC | Proprietary Name | Non-Proprietary Name | Dosage Form | Route Name | Company Name | Status | |
|---|---|---|---|---|---|---|---|
| 73153-900 | Breyanzi | Lisocabtagene Maraleucel | Kit | Juno Therapeutics, Inc. | ACTIVE |
